Liver cancer in severe alpha-1 antitrypsin deficiency: who is at risk?

Affiliations

¹ Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
² Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany pstrnad@ukaachen.de.

Free article

Comment

Malin Fromme et al. Eur Respir J. 2022.

Free article

. 2022 Nov 3;60(5):2200718.

doi: 10.1183/13993003.00718-2022. Print 2022 Nov.

¹ Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
² Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany pstrnad@ukaachen.de.

No abstract available

Conflict of interest statement

Conflict of interest: M. Fromme has nothing to disclose. P. Strnad has nothing to disclose.

Cancer risk in severe alpha-1-antitrypsin deficiency.
Hiller AM, Ekström M, Piitulainen E, Lindberg A, Rönmark E, Tanash H. Hiller AM, et al. Eur Respir J. 2022 Oct 27;60(4):2103200. doi: 10.1183/13993003.03200-2021. Print 2022 Oct. Eur Respir J. 2022. PMID: 35361631